Subscribe to RSS
DOI: 10.1055/s-0043-1771283
Use of Oral Empagliflozin to Obtain Optimal Blood Sugar Levels for Conducting 18F-FDG PET-CT in Patients with Hyperglycemia—A Pilot Study
Funding None.
Abstract
Background Flourine-18 fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) is a well-established imaging modality for the evaluation of patients with oncological and nononcological conditions. The underlying principle of imaging is the preferentially increased glucose consumption by cancer cells, due to overexpression of glucose type 1 receptors that are insulin independent. Thus, one of the factors that leads to decreased sensitivity of an 18F-FDG PET-CT is elevated blood sugar levels, leading to decreased glucose uptake by cancer cells due to competitive inhibition.
A significant percentage of patients scheduled for PET-CT scan has diabetes mellitus type II as a comorbid condition and often has elevated random blood sugar (RBS) precluding an upfront PET-CT evaluation. Such cases must be rescheduled. This causes delay in the evaluation and management of such patients.
Empagliflozin is a novel sodium glucose type 2 inhibitor that prevents tubular reabsorption of glucose and increases renal glycosuria resulting in decreased blood sugar. This drug does not cause significant hypoglycemia or increase endogenous insulin secretion. This study was undertaken to evaluate a potential role for empagliflozin in facilitating optimal blood sugar control in patients with hyperglycemia on the day of the scheduled PET scan.
Methods This is an interventional prospective study and patients detected to have RBS more than 200 mg/dL on the day of the scheduled scan were included in the study. The patients were administered two tablets of 10 mg empagliflozin and kept under observation. Samples for RBS were taken at approximately 2nd and 4th hour post administration by bedside method. These patients underwent scan on the same day after adequate sugar control and when an RBS of less than 200 mg/dL was achieved. The primary outcome studied was change in RBS values in the patient cohort and evaluation of PET SUV (standardized uptake value) compared with the rest of the patients scheduled on the same day. Secondary outcome was assessment of any side effects in the patients.
Results Total of 10 patients were found to have elevated blood sugar (RBS > 200 mg/dL; irrespective of being on medication) and did not meet the evaluation criteria for a PET-CT scan on the scheduled day. Following administration of the drug, all 10 patients were able to attain blood sugar levels and fulfill the criteria for undergoing a PET-CT scan. No obvious side effect was noted in any of the patient. The SUV values of the patient cohort were comparable with the rest of the patient scanned on the day.
Conclusion In this pilot study, 20 mg of empagliflozin (2 tablets of 10 mg) appears to be a safe and effective method for achieving optimal decrease in the RBS without causing hypoglycemia or hyperinsulinemia. It can be safely employed in the subset of population with RBS between 201 and 300 mg/dL to adequately bring the sugar levels at acceptable levels RBS less than 200 mg/dl and fulfill the FDG PET-CT criteria as per European Association of Nuclear Medicine (EANM) norms.
Authors' Contributions
All authors contributed to the study conception and design. All authors read and approved the final manuscript.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Ethical Approval
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the hospital.
Informed Consent
Informed consent was obtained from all individual participants included in the study to share their medical data for the purpose of publishing.
Publication History
Article published online:
06 September 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Accessed June 25, 2023, at: https://www.eanm.org/publications/guidelines/2015_GL_PET_CT_TumorImaging_V2.pdf
- 2 Dai KS, Tai DY, Ho P. et al. Accuracy of the Easytouch blood glucose self-monitoring system: a study of 516 cases. Clin Chim Acta 2004; 349 (1–2): 135-141
- 3 Eskian M, Alavi A, Khorasanizadeh M. et al. Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements. Eur J Nucl Med Mol Imaging 2019; 46 (01) 224-237
- 4 Caobelli F, Pizzocaro C, Paghera B, Guerra UP. Proposal for an optimized protocol for intravenous administration of insulin in diabetic patients undergoing (18)F-FDG PET/CT. Nucl Med Commun 2013; 34 (03) 271-275
- 5 Bui KL, Horner JD, Herts BR, Einstein DM. Intravenous iodinated contrast agents: risks and problematic situations. Cleve Clin J Med 2007; 74 (05) 361-364 , 367
- 6 Accessed June 25, 2023, at: https://www.acr.org/-/media/ACR/files/clinical-resources/contrast_media.pdf
- 7 Accessed June 25, 2023, at: https://radiology.ucsf.edu/patient-care/patient-safety/contrast/iodinated#accordion-contrast-administration-in-patients-receiving-metformin
- 8 Ndefo UA, Anidiobi NO, Basheer E, Eaton AT. Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P&T 2015; 40 (06) 364-368
- 9 Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75 (12) 1272-1277 DOI: 10.1038/ki.2009.87. . PMID: 19357717
- 10 Food and Drug Administration FDA approves Jardiance to treat type-2 diabetes. Aug 1, 2014. Accessed June 25, 2023, at: https://www.boehringer-ingelheim.com/us/press-release/fda-approves-jardiance-empagliflozin-tablets-adults-type-2-diabetes
- 11 Grempler R, Thomas L, Eckhardt M. et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14 (01) 83-90 DOI: 10.1111/j.1463-1326.2011.01517.x. . PMID: 21985634
- 12 Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle HJ. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15 (07) 613-621 DOI: 10.1111/dom.12073. . PMID: 23356556
- 13 Jardiance (empagliflozin) prescribing information. Ridgefield, Connecticut: Boehringer Ingelheim Pharmaceuticals; 2014